Enritinib is an oral bioavailable inhibitor of tyrosine kinase tropomyosin receptor kinases (Trk) A, B, and C, C-ros oncogene 1 (ROS1), and anaplastic lymphoma kinase (ALK), with potential anti-tumor activity. After administration, enrotinib binds and inhibits TrkA, TrkB, TrkC, ROS1, and ALK. Inhibiting these kinases may lead to interruption of signal transduction mediated by TrkA -, TrkB -, TrkC -, ROS1-, and ALK. This leads to induction of apoptosis and inhibition of tumor cell proliferation in tumor cells expressing these kinases. TrkA, TrkB, TrkC, ROS1, and ALK are overexpressed in various types of cancer cells.